[
    "{\"step_by_step_thinking\": \"To determine whether first-line single-agent mitoxantrone is as effective as combination chemotherapy in the treatment of high-risk metastatic breast cancer patients, we need to consider the available evidence. We can start by reviewing relevant clinical trials and studies comparing the two treatment approaches. Additionally, we should consider factors such as overall survival rates, progression-free survival, response rates, and adverse effects associated with each treatment option. By analyzing this information, we can determine if there is a clear answer to the question.\", \"answer_choice\": \"B. no\"}"
]